Curriculum · Nephrology and Urology
Potassium homeostasis and transcellular shift
What it is
Potassium is an intracellular electrolyte, and that one fact explains most of what it does. It is highly influenced by physiological factors:
- Insulin
- pH
- Catecholamines
The main endocrine controlling force is RAAS. The symptomology of potassium is cardiac and neuromascular, so muscle weakness and lethargy belong to it.
How it is treated
The most important initial treatment to lower a high serum potassium is insulin-dextrose. Insulin shifts potassium into cells by stimulating the activity of the Na+-H+ antiporter on the cell membrane, promoting the entry of sodium into cells, which leads to activation of the Na+-K+ ATPase, causing an electrogenic influx of potassium.
IV bicarbonate, oral resonium and IV calcium gluconate are not the most important initial treatment to lower the serum potassium level. A potassium of 6.8 mmol/L with muscle weakness and lethargy is the kind of level at which this question is asked.
What can go wrong
The transcellular shift cuts both ways, and diabetic ketoacidosis is where it is seen best. Starting insulin replacement leads to a transcellular potassium shift intra-cellularly. Total body potassium is already in deficit, given the osmotic diuresis, and it gets worse with insulin. A potassium that reads 3.7 mmol/L before treatment can fall to 2.9 mmol/L after therapy is started.
That is why the treatment regimen for diabetic ketoacidosis is built the way it is:
- Prophylactic potassium, IV insulin and IV fluids
- Volume replacement with crystalloids
- Electrolytes correction, mainly K and PO4
- IV insulin with or without dextrose, continued until the acidosis and anion gap are corrected and the patient is able to take orally
- Once the anion gap closes: subQ insulin
- Once blood glucose reaches 200-250 mg/dL: D5W, which is there to prevent hypoglycemia
Monitor K, Mg and PO4.